1 / 1

Structure of Ad-TRE-SRFc7: Enhanced Adenoviral Vector for Gene Therapy Applications

The Ad-TRE-SRFc7 vector is engineered for gene therapy, showcasing a capacity of approximately 5.1 Kb. It features ITRs derived from Adenovirus serotype 5, with a precise E1 deletion replaced by an E3 deletion. This vector employs a minimal CMV promoter along with a β-globin polyadenylation signal to ensure effective expression. The inclusion of the CMV TATAA box and 5' UTR enhances transcriptional efficiency, making this construct suitable for therapeutic applications in gene delivery and expression studies.

juro
Télécharger la présentation

Structure of Ad-TRE-SRFc7: Enhanced Adenoviral Vector for Gene Therapy Applications

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Structure of Ad-TRE-SRFc7 33,571 bp Capacity ~5.1 Kbp ITR ITR Adenovirus serotype 5 E1 deletion replaced by: E3 deletion minCMV SRFc7 b-globin pA 7 tetO minCMV = CMV TATAA box and 5’ UTR

More Related